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Conclusions: HCV p7 protein is a trans-regulator. The
expression of p7 protein affected the expression spectrum
of HCV infected hepatocyte.
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Introduction: Patients who have undergone kidney
transplantation (TX) and suffer from hepatic C related
(HCV) cannot be treated with standard therapy (PEG-
IFN combined with ribavirin) due to acute rejection
risk. Furthermore, immuno-suppressive therapy facilitates
progression and infection and chronic hepatopathesis.
Monocytes and macrophages are known to produce extra-
hepatic breeding sites and spread disease. Our aim was
to lower macrophages, granulocytes, monocytes, pro-
inﬂammatory cells and viremia levels using an extra-
corporeal device:Adacolumn® (Otsuka).
Methods: The Adacolumn ﬁlter is ﬁlled with 2mm cellulose
acetate beads immersed in sterile saline solution. These
carriers absorb granulocytes and monocytes/macrophages
through FCR receptors. Six patients were treated in our
department. All patients were affected by virale genotype
1b. Inclusion criteria: kidney transplant at under one year
and HCV-RNA >800,000 copies. Patients underwent ﬁve
1-hour treatments for ﬁve consecutive days according to
protocol. Kidney and hepatic parameters were evaluated as
were changes in immuno-modulation (CD4, CD8) and HCV-
RNA base quantities, at end of treatment and at 1 month,
2 month and 3 month follow ups.
Results: During treatment cycles and successive follow ups
we observed a stabilization of kidney parameters and a non
signiﬁcant decrease in transaminase levels. At 3rd month
follow up we observed a signiﬁcant decrease in plasma
HCV-RNA in 3 patients (p < 0.01) associated with attenuation
of inﬂammatory phase (p < 0.2) and variations in immuno-
modulation. Only one patient presented altered CD4+ and
CD8+ where positive was observed at 3rd month. In another
patient, even though immuno- modulation improved, there
was no reduction in viremia.
Conclusions: The treatment was found to be safe without
hemodynamic or infective complications. Considering the
results this method should be used on a greater number of
patients evaluating successive treatment times in case of
viremia increase.
